Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Aug 10, 2026
Silence Therapeutics plc (SLN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $12.3 million. Free cash flow was $1.5 million. As of Jun 30, 2026 it held $72.1 million in cash and investments and $112,000 in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-12.27M
+55.2% vs year-ago quarter
Operating cash flow
$1.52M
+107.0% vs year-ago quarter
Free cash flow
$1.52M
+107.0% vs year-ago quarter
EPS
$-0.09
+52.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
141.74M
+0.0% vs year-ago quarter
Net cash
$71.94M
Q2 FY2026
Operating margin
-11106.8%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SLN (Nasdaq), SLNCF (OTC)
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1479615
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $422,000 | $34,000 | $159,000 | $224,000 |
| Operating income | -$13.9M | -$15.7M | -$12.5M | -$26.2M | -$24.0M |
| Net income | -$12.3M | -$15.0M | -$11.8M | -$21.0M | -$27.4M |
| Diluted EPS | -$0.09 | -$0.11 | -$0.08 | -$0.15 | -$0.19 |
| Operating cash flow | $1.5M | -$15.6M | -$17.3M | -$10.9M | -$21.8M |
| Free cash flow | $1.5M | -$15.6M | -$17.3M | -$10.9M | -$21.8M |
| Total assets | $106.4M | $115.1M | $131.4M | $146.8M | $165.2M |
| Total liabilities | $67.9M | $65.7M | $69.1M | $72.7M | $71.1M |
| Stockholders' equity | $38.5M | $49.4M | $62.3M | $74.1M | $94.2M |
| Cash and investments | $72.1M | $70.1M | $85.1M | $102.2M | $114.2M |
| Total debt | $112,000 | $136,000 | $160,000 | $182,000 | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 19, 2026 | Oct 18, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 12, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 16, 2026 | Jul 10, 2026 |
All 275 Silence Therapeutics plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.